CareDx, Inc (NASDAQ:CDNA) Shares Sold by Thrivent Financial for Lutherans
Posted by MarketBeat News on Apr 1st, 2025 Thrivent Financial for Lutherans lessened its stake in CareDx, Inc (NASDAQ:CDNA – Free Report) by 28.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 57,939 shares of the company’s stock after selling 23,392 shares during the quarter. Thrivent Financial for Lutherans’ holdings in CareDx were worth $1,240,000 as of its most recent SEC filing. Several other institutional investors have also recently added to or reduced their stakes in CDNA. Virtue Capital Management LLC acquired a new position in shares of CareDx in the 3rd quarter worth approximately $755,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in CareDx during the third quarter worth $1,671,000. Geode Capital Management LLC boosted its holdings in CareDx by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company’s stock worth $38,343,000 after purchasing an additional 32,141 shares during the period. Barclays PLC increased its stake in CareDx by 123.8% during the third quarter. Barclays PLC now owns 98,505 shares of the company’s stock valued at $3,075,000 after purchasing an additional 54,482 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of CareDx by 1.9% during the fourth quarter. Swiss National Bank now owns 98,600 shares of the company’s stock worth $2,111,000 after purchasing an additional 1,800 shares during the period. Wall Street Analysts Forecast Growth Several research firms have recently commented on CDNA. HC Wainwright decreased their price target on shares of CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Stephens restated an “overweight” rating and issued a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and reduced their price objective for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.83. Check Out Our Latest Research Report on CDNACareDx Trading Down 1.2 % Shares of NASDAQ CDNA opened at $17.75 on Tuesday. CareDx, Inc has a 12-month low of $7.42 and a 12-month high of $34.84. The company has a market cap of $983.81 million, a PE ratio of -6.57 and a beta of 1.95. The stock has a 50 day simple moving average of $21.32 and a 200-day simple moving average of $23.52. CareDx (NASDAQ:CDNA – Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $86.58 million during the quarter, compared to analysts’ expectations of $84.56 million. Sell-side analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current fiscal year. CareDx Company Profile (Free Report) CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Read More Five stocks we like better than CareDx Consumer Staples Stocks, Explained 3 Buyable Stocks With Solid Bottoms Ready to Rebound The Basics of Support and Resistance Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star CD Calculator: Certificate of Deposit Calculator Robotaxi News: What Tesla and Lyft Headlines Mean for Shares Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc (NASDAQ:CDNA – Free Report). Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEThrivent Financial for Lutherans Lowers Position in Dynavax Technologies Co. (NASDAQ:DVAX) NEXT HEADLINE »Thrivent Financial for Lutherans Buys 6,665 Shares of Stanley Black & Decker, Inc. (NYSE:SWK) You might be interested in: